Kura Oncology Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
So hello, everyone. Thanks for joining us. My name is Jonathan Chang. I'm part of the SVB Leerink Equity Research Team. It's my pleasure to host the management team of Kura. And we have with us today, President and CEO, Troy Wilson. So thank you very much for joining us. For the investors that are joining us, feel free to submit questions or e-mail them to me at [email protected].
And with that, let's get started. Troy, would you please briefly introduce the company?
Sure, Jonathan, and thank you, and thanks to SVB Leerink for the opportunity to participate and to do this virtual fireside chat.
Kura is a precision oncology company focused on developing targeted therapies for the treatment of cancer. We have two programs, KO-539, which is targeting genetically defined subsets of acute leukemia by targeting a protein-protein interaction that is essential for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |